Cellectricon Partners with The Automation Partnership
News Dec 04, 2008
Cellectricon has announced the signing of a collaborative agreement with The Automation Partnership (TAP) in the UK, manufacturers of advanced automated systems for cell culture, sample management and high throughput screening applications.
Under the agreement TAP will co-develop and manufacture the Dynaflow®HT System, Cellectricon’s next generation high throughput ion channel screening platform. Dynaflow®HT will be launched and commercially available in 2009.
Addressing the limitations of current ion channel screening technologies, the Dynaflow®HT yields a level of automated throughput while still delivering measurement data quality. The concept and technology has been developed and validated over the last three years by Cellectricon in partnership with AstraZeneca.
“We are excited to partner with TAP who are world-renowned for manufacturing industrial quality automation”, says Jonas Ohlsson, CEO at Cellectricon. “To bring this fully automated state-of-the-art high throughput electrophysiology system to the market is a milestone for ion channel screening. The system offers unmatched throughput, cost per data point and reliability/predictability”.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE